Sibrotuzumab

Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP) . Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) [1].

Product Specifications

CAS Number

[216669-97-5]

Product Name Alternative

BIBH 1; Anti-Human FAP Recombinant Antibody

UNSPSC

12352203

Target

FAP

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sibrotuzumab.html

Purity

99.05

Solubility

10 mM in DMSO

Smiles

[Sibrotuzumab]

Molecular Weight

(148.66 kDa)

References & Citations

[1]Scott AM, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9 (5) :1639-47.|[2]Kobayashi T, et al., Near-infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts in Patient-Derived Xenografts Using a Humanized Anti-Fibroblast Activation Protein Antibody. Mol Cancer Ther. 2024 Jul 2;23 (7) :1031-1042.